Autologous Bone Marrow For Lower Extremity Ischemia Treating
Primary Purpose
Lower Extremity Ischemia
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Bone marrow aspiration, injection of cells
Bone marrow aspiration , injection of isolated CD 133+ cells
Bone marrow aspiration, injection of saline
Sponsored by

About this trial
This is an interventional treatment trial for Lower Extremity Ischemia focused on measuring lower extremity ischemia, Bone marrow, Progenitor cells, Neoangiogenesis
Eligibility Criteria
Inclusion Criteria:
- an obliterating lower extremity atherosclerosis IIB a stage (on Fontaine classification)
- a painless walking distance of 10-50 m
- pulse absence on аа. dorsalis pedis, tibialis posterior, poplitea
- absence of a ischemia in a rest and necrotic changes
- mainly distal form of disease (a lesion of a superficial femoral artery, a popliteal artery, anticnemion arteries) according to an angiography that testifies to impossibility of reconstructive operation performance
- patients after a lumbar sympathectomy and a tibial bone osteoperforations executed previously
- heavy smokers
Exclusion Criteria:
- insulin depended diabetes
- myocardial infarction or a stroke within last year
- an idiopathic hypertensia III stage
- anaemia and other diseases of blood
- decompensation of the chronic diseases which are contraindications to any surgical operation
- HIV infection
- a virus hepatitis
- oncologic diseases
- chemotherapy in the anamnesis
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
CD133
TNC
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Increasing of painless walking distance
Secondary Outcome Measures
Full Information
NCT ID
NCT00753025
First Posted
September 9, 2008
Last Updated
September 15, 2008
Sponsor
Clinical Center of Cellular Technologies, Russia
Collaborators
Samara State Medical University, Regional hospital of Samara
1. Study Identification
Unique Protocol Identification Number
NCT00753025
Brief Title
Autologous Bone Marrow For Lower Extremity Ischemia Treating
Official Title
Randomized Double Blind Placebo-Controlled Research Of Treatment Efficiency For Patients With Lower Extremity Arteriosclerosis Obliterans By Autologous Transplantation Of Bone Marrow Progenitor Cells
Study Type
Interventional
2. Study Status
Record Verification Date
September 2008
Overall Recruitment Status
Completed
Study Start Date
October 2006 (undefined)
Primary Completion Date
June 2007 (Actual)
Study Completion Date
February 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Clinical Center of Cellular Technologies, Russia
Collaborators
Samara State Medical University, Regional hospital of Samara
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether autologous bone marrow derived cells and isolated CD133+ fraction are effective in the treatment limb ischemia
Detailed Description
The number of patients with low limb obliterating atherosclerosis steadily grows and compounds more than 20-25 % from all kinds of a cardiovascular pathology. At conservation of this tendency to 2020 the amputation percentage executed due to vessel diseases, can reach 45 %. Hemodynamics improvement in an extremity by surgery is possible at 40 - 70 % of patients even with the widespread and plural lesion of arteries, but results are not always satisfactory. The most actual is the problem of angiosurgical help to patients with distal forms of arterial occlusions, due to the difficulty or impossibility performing reconstructive interventions. In these cases the operations of an indirect revascularization referred on stimulation of a collateral blood flow are carried out. However, despite the reached successes, in some cases results of such interventions do not give desirable effect, search of new methods of treatment therefore is necessary. To date the most perspective methods of neoangiogenesis stimulation are a cellular therapy and gene-engineering technologies. Experimental researches on a model of local limb ischemia showed possibility of use of various cells for neoangiogenesis stimulation. A number of clinical researches at patients with obliterating limb diseases has shown efficacy of cellular therapy even at a critical ischemia. However randomized, the placebo-controlled researches based on principles of evidence based medicine while it is not enough for the convincing conclusions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lower Extremity Ischemia
Keywords
lower extremity ischemia, Bone marrow, Progenitor cells, Neoangiogenesis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CD133
Arm Type
Experimental
Arm Title
TNC
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Procedure
Intervention Name(s)
Bone marrow aspiration, injection of cells
Intervention Description
Bone marrow is aspirated at patients in all arms.
Arm "TNC" receives injection of total nucleated cells into ischemic muscle
Intervention Type
Procedure
Intervention Name(s)
Bone marrow aspiration , injection of isolated CD 133+ cells
Intervention Description
arm "CD133" receives injection of isolated CD 133+ cells
Intervention Type
Procedure
Intervention Name(s)
Bone marrow aspiration, injection of saline
Intervention Description
arm "placebo" receives injection of saline
Primary Outcome Measure Information:
Title
Increasing of painless walking distance
Time Frame
Within the first 30 days, 6 months and 12 months after injection
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
39 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
an obliterating lower extremity atherosclerosis IIB a stage (on Fontaine classification)
a painless walking distance of 10-50 m
pulse absence on аа. dorsalis pedis, tibialis posterior, poplitea
absence of a ischemia in a rest and necrotic changes
mainly distal form of disease (a lesion of a superficial femoral artery, a popliteal artery, anticnemion arteries) according to an angiography that testifies to impossibility of reconstructive operation performance
patients after a lumbar sympathectomy and a tibial bone osteoperforations executed previously
heavy smokers
Exclusion Criteria:
insulin depended diabetes
myocardial infarction or a stroke within last year
an idiopathic hypertensia III stage
anaemia and other diseases of blood
decompensation of the chronic diseases which are contraindications to any surgical operation
HIV infection
a virus hepatitis
oncologic diseases
chemotherapy in the anamnesis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olga Tyumina, PhD
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Autologous Bone Marrow For Lower Extremity Ischemia Treating
We'll reach out to this number within 24 hrs